ContributorsPublishersAdvertisers

No Viability in Adding Chemotherapy to Novel Regimens in CLL

targetedonc.com
 2021-11-24

Cover picture for the articlePhase 1b results indicate no benefit when chemotherapy is added to novel regimens for chronic lymphocytic leukemia. Adding bendamustine to venetoclax (Venclexta) plus rituximab (Rituxan), or Ven-BR, appeared to increase toxicity in patients with chronic lymphocytic leukemia (CLL) and did not show efficacy benefit when compared with venetoclax plus bendamustine and...

www.targetedonc.com

Comments / 0

Comments / 0